Portolan Capital Management LLC Purchases 30,704 Shares of Establishment Labs Holdings Inc. $ESTA

Portolan Capital Management LLC grew its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 24.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 155,096 shares of the company’s stock after purchasing an additional 30,704 shares during the quarter. Portolan Capital Management LLC’s holdings in Establishment Labs were worth $6,357,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in ESTA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Establishment Labs by 20.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after purchasing an additional 9,557 shares during the last quarter. Geode Capital Management LLC grew its holdings in Establishment Labs by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after buying an additional 299 shares during the last quarter. SG Americas Securities LLC increased its position in Establishment Labs by 94.2% in the 2nd quarter. SG Americas Securities LLC now owns 8,712 shares of the company’s stock worth $372,000 after buying an additional 4,226 shares during the period. ARS Investment Partners LLC bought a new position in Establishment Labs in the 2nd quarter worth approximately $278,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Establishment Labs by 0.5% during the second quarter. JPMorgan Chase & Co. now owns 373,112 shares of the company’s stock worth $15,936,000 after buying an additional 1,719 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $63.35 on Friday. The firm has a market capitalization of $1.86 billion, a PE ratio of -36.41 and a beta of 0.91. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $83.31. The business’s 50 day moving average is $70.25 and its 200-day moving average is $60.41.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.Establishment Labs’s revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company posted ($1.19) earnings per share. Sell-side analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Stephens increased their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. BTIG Research upped their target price on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. increased their price target on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Citigroup decreased their price target on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.